Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$30.14 -1.7%	$33.64	$21.62 ▼ $39.47	$5.83B	1.08	2.23 million shs	3.54 million shs
GLPG Galapagos	$23.52 +2.1%	$25.13	$22.36 ▼ $31.99	$1.55B	0.16	189,466 shs	351,430 shs
LEGN Legend Biotech	$30.77 +1.7%	$35.79	$29.31 ▼ $60.87	$5.65B	0.21	1.21 million shs	1.23 million shs
RVMD Revolution Medicines	$31.13 -0.9%	$39.03	$29.17 ▼ $62.40	$5.84B	1.37	1.42 million shs	2.84 million shs

20 Stocks to Sell Now

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-1.73%	-8.72%	-4.53%	+2.34%	+6.61%
GLPG Galapagos	+2.08%	-5.05%	-11.51%	-16.51%	-26.18%
LEGN Legend Biotech	+1.72%	-2.38%	-12.73%	-6.10%	-43.85%
RVMD Revolution Medicines	-0.86%	-7.41%	-20.61%	-29.92%	-2.44%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.5207 of 5 stars	4.5	2.0	3.9	2.7	4.2	0.6
GLPG Galapagos	0.5273 of 5 stars	0.8	4.0	0.0	2.1	0.0	0.6
LEGN Legend Biotech	2.6114 of 5 stars	3.5	3.0	0.0	3.4	1.7	0.6
RVMD Revolution Medicines	4.0221 of 5 stars	4.5	0.0	4.7	2.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$52.64	74.64% Upside
GLPG Galapagos	1.50	Reduce	$25.33	7.71% Upside
LEGN Legend Biotech	2.92	Moderate Buy	$79.00	156.74% Upside
RVMD Revolution Medicines	3.08	Buy	$65.23	109.54% Upside

Current Analyst Ratings Breakdown

Latest GLPG, BBIO, RVMD, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00 ➝ $59.00
4/1/2025	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $64.00
3/31/2025	BBIO BridgeBio Pharma	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
3/24/2025	BBIO BridgeBio Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$44.00 ➝ $50.00
3/17/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$82.00 ➝ $80.00
3/12/2025	LEGN Legend Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/12/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $75.00
3/3/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $73.00
2/27/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
2/27/2025	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00

(Data available from 4/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	25.83	N/A	N/A	($7.71) per share	-3.91
GLPG Galapagos	$275.65M	5.62	N/A	N/A	$47.57 per share	0.49
LEGN Legend Biotech	$627.24M	9.01	N/A	N/A	$6.88 per share	4.47
RVMD Revolution Medicines	$742K	7,799.83	N/A	N/A	$11.09 per share	2.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$2.85	N/A	N/A	N/A	-241.44%	N/A	-75.69%	5/1/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	4/23/2025 (Estimated)
LEGN Legend Biotech	-$518.25M	-$0.48	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	5/12/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$3.57	N/A	N/A	N/A	N/A	-33.67%	-30.08%	5/6/2025 (Estimated)

Latest GLPG, BBIO, RVMD, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	BBIO BridgeBio Pharma	-$0.90	N/A	N/A	N/A	$57.14 million	N/A
4/23/2025	Q1 2025	GLPG Galapagos	-$0.19	N/A	N/A	N/A	$72.22 million	N/A
3/11/2025	Q4 2024	LEGN Legend Biotech	-$0.39	$0.07	+$0.46	$0.07	$179.00 million	$186.50 million
2/26/2025	Q4 2024	RVMD Revolution Medicines	-$1.01	-$1.12	-$0.11	-$1.12	$0.35 million	N/A
2/20/2025	Q4 2024	BBIO BridgeBio Pharma	-$1.09	-$1.31	-$0.22	-$1.40	$4.04 million	$5.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
GLPG Galapagos	N/A	9.97	9.81
LEGN Legend Biotech	0.27	4.98	4.90
RVMD Revolution Medicines	N/A	14.24	14.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
GLPG Galapagos	32.46%
LEGN Legend Biotech	70.89%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	24.66%
GLPG Galapagos	2.91%
LEGN Legend Biotech	0.02%
RVMD Revolution Medicines	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	190.19 million	143.29 million	Optionable
GLPG Galapagos	1,310	65.90 million	63.98 million	Optionable
LEGN Legend Biotech	1,070	183.65 million	182.60 million	Optionable
RVMD Revolution Medicines	250	185.91 million	154.76 million	Optionable

GLPG, BBIO, RVMD, and LEGN Headlines

Recent News About These Companies

Revolution Medicines, Inc. (NASDAQ:RVMD) Stake Decreased by Finepoint Capital LP

April 8 at 6:06 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Geode Capital Management LLC

April 8 at 4:28 AM | marketbeat.com

Financial Survey: Quince Therapeutics (NASDAQ:QNCX) versus Revolution Medicines (NASDAQ:RVMD)

April 8 at 2:06 AM | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Hits New 1-Year Low - Here's Why

April 7 at 8:27 PM | marketbeat.com

ExodusPoint Capital Management LP Acquires Shares of 123,315 Revolution Medicines, Inc. (NASDAQ:RVMD)

April 7 at 4:48 AM | marketbeat.com

California Public Employees Retirement System Has $11.74 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 7 at 4:00 AM | marketbeat.com

75,000 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Pamalican Asset Management Ltd

April 6 at 7:23 AM | marketbeat.com

Cinctive Capital Management LP Has $1.52 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 6 at 5:08 AM | marketbeat.com

Headlands Technologies LLC Reduces Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 6 at 4:50 AM | marketbeat.com

Bryce Point Capital LLC Invests $808,000 in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 5, 2025 | marketbeat.com

B. Metzler seel. Sohn & Co. AG Makes New $752,000 Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 5, 2025 | marketbeat.com

1,742,039 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Norges Bank

April 4, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Price Target Cut to $64.00 by Analysts at Stifel Nicolaus

April 2, 2025 | marketbeat.com

Wellington Management Group LLP Has $473.34 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 2, 2025 | marketbeat.com

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

April 1, 2025 | globenewswire.com

Pictet Asset Management Holding SA Increases Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 1, 2025 | marketbeat.com

23,504 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by KLP Kapitalforvaltning AS

April 1, 2025 | marketbeat.com

Revolution Medicines to Participate in April 2025 Investor Conferences

March 31, 2025 | globenewswire.com

Vanguard Group Inc. Purchases 2,185,082 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

March 31, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by NEOS Investment Management LLC

March 30, 2025 | marketbeat.com

American Century Companies Inc. Increases Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

March 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLPG, BBIO, RVMD, and LEGN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$30.14 -0.53 (-1.73%)

Closing price 04/8/2025 04:00 PM Eastern

Extended Trading

$31.02 +0.88 (+2.92%)

As of 04/8/2025 07:56 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Galapagos NASDAQ:GLPG

$23.52 +0.48 (+2.08%)

Closing price 04/8/2025 04:00 PM Eastern

Extended Trading

$23.52 0.00 (0.00%)

As of 04/8/2025 04:50 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Legend Biotech NASDAQ:LEGN

$30.77 +0.52 (+1.72%)

Closing price 04/8/2025 04:00 PM Eastern

Extended Trading

$30.77 0.00 (0.00%)

As of 04/8/2025 07:41 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Revolution Medicines NASDAQ:RVMD

$31.13 -0.27 (-0.86%)

Closing price 04/8/2025 04:00 PM Eastern

Extended Trading

$31.13 0.00 (0.00%)

As of 04/8/2025 07:04 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time